A 35-year-old man with moderate persistent asthma well-controlled on inhaled fluticasone 250 µg twice daily presents with a 2-week history of increased daytime symptoms (4–5 days per week) and nocturnal awakening twice per week. He denies recent upper respiratory infection or medication non-adherence. Spirometry shows FEV₁ 65% predicted. What is the most appropriate next step in management?

Explanation

## Assessment of Control and Step-Up Therapy This patient has **loss of asthma control** on Step 2 therapy (low-dose ICS). The presence of daytime symptoms 4–5 days per week and nocturnal awakening twice per week indicates inadequate control and the need for step-up therapy to Step 3. ### GINA Stepwise Approach for Step-Up Therapy ```mermaid flowchart TD A["Asthma on low-dose ICS<br/>(Step 2)"]:::outcome --> B{"Loss of control?<br/>Daytime ≥2 days/week<br/>or nocturnal symptoms"}:::decision B -->|Yes| C["Step 3: Add LABA<br/>to ICS"]:::action B -->|No| D["Continue Step 2<br/>Review in 3 months"]:::action C --> E{"Combination ICS/LABA<br/>or separate inhalers?"}:::decision E -->|Preferred| F["Combination ICS/LABA<br/>inhaler"]:::action E -->|Alternative| G["Separate ICS + LABA<br/>inhalers"]:::action F --> H["Reassess in 4 weeks"]:::outcome ``` **High-Yield:** Loss of control on Step 2 → Step 3 = Add LABA to ICS (not increase ICS dose alone). ### Why Combination ICS/LABA is Preferred Over ICS Dose Escalation | Approach | Efficacy | Safety | GINA Recommendation | |---|---|---|---| | Increase ICS dose alone | Modest improvement | Increased systemic absorption | Not preferred for step-up | | Add LABA to low-dose ICS | Superior symptom control + exacerbation reduction | Safe; LABA always with ICS | **Preferred (Step 3)** | | Combination ICS/LABA inhaler | Equivalent to separate inhalers | Better adherence | **Most preferred** | **Key Point:** LABA is never used as monotherapy. Combination inhalers improve adherence and ensure ICS is always given with LABA (reducing LABA-related mortality risk). **Clinical Pearl:** The FEV₁ of 65% predicted (moderate airflow obstruction) also supports step-up to Step 3 therapy; ICS dose escalation alone is insufficient for this degree of airway obstruction. **Mnemonic:** GINA Step 3 = ICS + LABA (not ICS alone at higher dose).